Articles tagged with Breast Cancer
Researchers developed a metal-free carbon monoxide prodrug that significantly reduced metastatic tumor growth in pancreatic and triple-negative breast cancer models without signs of toxicity. The prodrug, CO-116, works by disrupting a signaling pathway that promotes cancer cell migration and metastasis.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
A study published in Radiology found that three commercially available AI-based computer-assisted detection (AI-CAD) systems can identify early mammographic signs of breast cancer up to 6 years before diagnosis. This could help radiologists spot potential future cancers and allow for earlier intervention.
Researchers identified specific gene mutations and characteristics associated with early-onset breast cancer in young Black women. The study highlights the importance of genetic testing for this population, which faces lower screening rates than other groups.
Researchers found that DHED increased estrogen specifically in the brain of aged marmosets, leading to improved memory and sleep. The treatment also reversed neural changes caused by letrozole, a common breast cancer treatment. However, DHED had different effects on body temperature regulation in males and females.
A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.
Researchers discover that breast cancer cells exploit protective systems in bone marrow to remain dormant, using Notch2 signaling and genes like CXCR4 and TIE2. This dormancy allows cells to reactivate years later, leading to secondary tumors.
A retrospective analysis of over 110,000 women found that GLP-1 medication users were 30% less likely to develop breast cancer. The study suggests that GLP-1s may inhibit tumor growth and reduce systemic inflammation, which could play a role in breast cancer development.
Prediagnostic statin use showed no association with higher survival rates, but postdiagnostic use was linked to lower all-cause and breast cancer-specific mortality among hormone receptor-positive subtypes. Statin therapy may improve survival of these patient groups.
Researchers used an open-source AI model called Mirai to quickly identify high-risk patients and expedite their diagnostic process. This led to a significant reduction in wait times, with some women receiving biopsy results within days of having their mammograms done.
A comprehensive review of breast cancer risk models in women with a family history found that none are highly accurate at identifying which women will develop the disease. The BOADICEA model showed balanced performance, while others had significant limitations, emphasizing the need for continued improvement.
Adding fovinaciclib to first-line aromatase inhibitor therapy confers significant progression-free survival benefits and consistent improvements in efficacy outcomes. The treatment also has manageable safety profiles with no negative impact on quality of life.
The study found that population-based pathogenic variant testing reveals different subsets of high-risk women than clinical risk factors and polygenic risk scores. This highlights the importance of incorporating PV testing into risk-based screening for breast cancer.
Researchers from Ohio State University Comprehensive Cancer Center present new findings on a hospital program that redistributes unused oral cancer drugs donated by patients. The program helps patients avoid treatment delays caused by insurance issues, shipping problems or cost, and has been shown to reduce drug delays by six days.
Researchers found that obesity alters the biological changes in breast cancer cells, enabling them to survive and thrive. The study's findings could improve prediction and treatment of invasive breast cancer, reducing overtreatment and unnecessary treatments.
A study published in Nature Communications has identified sialylation as a key mechanism by which breast tumours evade the immune system, leading to limited effectiveness of immunotherapies. Targeting this process may improve the efficacy of these therapies, providing new hope for patients with breast cancer.
A comprehensive study of Native American breast cancer tissue reveals molecular differences that may impact treatment efficacy. The study found unique patterns in gene mutations and immune system interactions, highlighting the need for personalized therapies.
Researchers at Lund University developed a blood test that can detect early signs of breast cancer recurrence, providing information on how the disease responds to chemotherapy. The method, called Pathlight, measures small fragments of tumor DNA in blood samples and detected recurrence up to four years before current methods.
Researchers found that smaller tetraploid cancer cells are more aggressive and tumorigenic, associated with worse prognosis and lower survival rates in several cancer types. This discovery challenges the conventional understanding of tetraploidy's role in cancer progression.
A novel chromosomal instability-based signature, CIN score, guides survival prediction and immunotherapy response in breast cancer. High-CIN scores indicate poorer overall survival and unfavorable clinicopathological features.
Researchers discover that kinases play a crucial role in moving cholesterol to activate a growth pathway in aggressive cancers. Without these enzymes, cancer cells are blocked from fueling tumor growth. The study highlights the importance of targeting lipid enzymes as a potential treatment strategy for cancers with TP53 mutations.
A new Ohio State University study aims to raise awareness of the link between alcohol consumption and breast cancer risk among young women. The study uses targeted messages to educate participants about the risks and encourage reduced drinking habits.
The MAF Test predicts breast cancer prognosis and helps identify patients who may benefit from treatment. In South Korea, the test could improve survival rates for approximately 34,000 newly diagnosed breast cancer patients each year.
Researchers discovered that overproduction of a DNA repair protein creates DNA damage mimicking BRCA mutations, which may respond to targeted treatments. Tumors with high levels of EXO1 protein exhibit characteristics similar to BRCA-mutant cells, suggesting personalized therapies could be effective.
Researchers from ECOG-ACRIN Cancer Research Group will present updated outcomes from the STAMP study on Merkel cell carcinoma, primary results from studies in glioblastoma and non-small cell lung cancer, and emerging approaches in precision oncology. AI-driven insights from the TAILORx breast cancer trial will also be showcased.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.
Researchers found that a common asthma drug can help fight aggressive cancers by blocking the CysLTR1 molecule. The study used mouse models and human tissue samples to demonstrate its potential in treating triple-negative breast cancer and other tough tumors.
Researchers are analyzing paired original and recurrent breast cancer tumors to identify biological factors driving recurrences years after treatment. The TAILORx and RxPONDER trials have provided a large dataset of clinically annotated tumor samples, enabling the study of late recurrence and potential prevention strategies.
A US-wide analysis of nearly 50 years of breast cancer data has found a major shift in outcomes and risk, highlighting gaps in prevention and treatment for specific groups. Breast cancer deaths are increasingly affecting younger women, while survival improved among older women over time.
Researchers found that stereotactic body radiotherapy (SBRT) improved progression-free survival by 15.6 months, compared to 20.6 months without targeted therapy. The treatment also showed no significant impact on quality-of-life measures.
The study found that stage IV breast cancer incidence increased across ages and sexes, while overall survival improved despite the increase. Researchers highlight the need for further investigation into factors contributing to the rise in incidence, including potential changes in breast cancer screening and other conditions.
Researchers have identified a hidden mechanism explaining why breast cancer can return years after successful treatment. Slow-growing breast cancer cells can form microscopic tumours that silently tick away in distant organs, evading detection for decades.
A cohort study found a potential association between GLP-1 RA use and improved survival rates among obese breast cancer patients with related metabolic conditions. Further evaluation of GLP-1 RA therapy in randomized clinical trials is warranted based on these findings.
A retrospective cohort study examining over 840,000 breast cancer patients found a potential link between GLP-1 RA use and improved outcomes among obese or diabetic patients. GLP-1 RAs were associated with lower risk of death and recurrence over a 10-year follow-up period.
Researchers at the University of Texas MD Anderson Cancer Center have identified specific blood-based genomic biomarkers that distinguish inflammatory breast cancer from other subtypes. The study used an improved method of RNA sequencing, called TGIRT sequencing, which allowed for a more comprehensive overview of all RNA types and amou...
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
Researchers developed a hand-held device to differentiate tumors from healthy tissue using mechanical properties, reducing the need for future surgeries and delayed treatments. The wireless probe can aid surgeons in precise tumor removal during breast-conserving surgery.
A study published in Cell Reports Medicine found that inhibiting RNase H2 can cause significant damage to DNA and activate the innate immune system to produce signals that attract T cells to attack the tumor. This approach could lead to improved patient outcomes for patients with triple-negative breast cancer.
A new study from Karolinska Institutet shows that low doses of endoxifen reduce breast density to the same extent as tamoxifen without causing severe side effects. The results suggest a lower dose may be sufficient for therapeutic effect while being better tolerated.
New technologies are shifting healthcare towards proactive care, using AI for early heart disease detection and miniaturized CRISPR-based diagnostics. These innovations enable seamless integration of existing medical screenings and provide laboratory-grade accuracy in a portable format.
Researchers found that NRG4, an adipokine secreted by white adipose tissue, suppresses breast cancer metastasis via ERBB4-YAP1 signaling. The study also showed that higher NRG4 levels correlate with improved patient survival outcomes.
A new liquid biopsy method has been developed to predict the response to immunotherapy in high-risk breast cancers. The study found that repeated blood sampling can assess and predict the evolving antitumor immune response to therapy, offering a potential tool for guiding immunotherapy decision-making.
A new survey found that nearly half of women incorrectly believe annual mammograms should start at age 50. Experts recommend yearly mammograms starting at age 40 for average-risk women. This delay can lead to cancers being found at a later stage, when treatment can be more complex.
Researchers at UTHealth Houston have discovered a new target for metastatic breast cancer treatments using experimental peptide therapy. The study found that the peptide BLMP6 targets fibulin-4, a protein expressed in high levels in metastatic breast cancers.
A new study combines dynamic full-field optical coherence tomography with deep learning to generate real-time virtual pathology images of fresh lymph nodes during surgery. The approach achieved high accuracy and sensitivity, reducing tissue consumption and manual workload.
Dr. Dennis Slamon, a renowned breast cancer researcher, has been elected to the Association of American Physicians (AAP) for his pioneering work in HER2 gene discovery and targeted therapies. His research led to significant improvements in survival rates and established the principle of targeted cancer treatment.
A cross-sectional study of patients with de novo metastatic breast cancer found racial and ethnic disparities in disease presentation. De novo metastatic breast cancer disproportionately contributes to breast cancer mortality in the U.S., emphasizing the need for tailored interventions to improve care delivery and outcomes.
Research from Lund University reveals that stiffer tumor tissue triggers a chain of molecular events driving cancer cells to invade surrounding tissue. The studies identified key proteins and pathways involved in this process, offering new insights into the mechanical properties of tumor microenvironments.
Researchers developed a microfluidic platform that squeezes individual breast epithelial cells to measure their mechanical age, revealing an unexpected insight: older cells are stiffer and at higher risk of cancer. The AI-powered platform provides a non-genetic test for women with unknown genetic risks.
Breast cancer cells that spread to the brain rely on a specific metabolic pathway to survive. Targeting this pathway with ACSS2 inhibitors can induce ferroptosis and shrink tumors in preclinical models.
The experimental drug DH20931 targets triple-negative breast cancer by triggering a surge in fat-like molecules called ceramides, overwhelming cancer cells with toxic fats. In lab experiments, the drug made standard chemotherapy more effective, reducing the dose needed to kill cancer cells by about fivefold.
Dr. Aditya Bardia has been elected to the American Society for Clinical Investigation for his outstanding contributions to research and patient care in breast cancer treatment. He is advancing precision medicine therapies through antibody-drug conjugates and liquid biopsy technologies.
Scientists at MUSC Hollings Cancer Center mapped the architecture of healthy breast tissue to uncover early biological changes linked to cancer risk. The study found that body weight and breast density shape the underlying structure of breast tissue, offering new clues about how cancer risk may develop long before tumors form.
Researchers have identified the Prrx1 gene as a key regulator of metastatic potential in breast cancer tumors. This discovery helps explain why highly invasive cells do not always give rise to metastases, and how cells combine invasiveness and proliferation to become the most dangerous from a clinical perspective.